fibroblast growth factor receptor 2
| UniProt | Protein Name |
|---|---|
| P21802 |
|
| D2CGD1 |
|
| S4R381 |
|
| A0A141AXF1 |
|
| GO Term | Evidence Code | PMID |
|---|---|---|
| negative regulation of transcription by RNA polymerase II | ||
| angiogenesis | ||
| angiogenesis | ||
| ureteric bud development | ||
| in utero embryonic development |
| GO Term | Evidence Code | PMID |
|---|---|---|
| cytoplasmic vesicle | ||
| receptor complex | ||
| excitatory synapse | ||
| collagen-containing extracellular matrix |
| GO Term | Evidence Code | PMID |
|---|---|---|
| protein tyrosine kinase activity | ||
| GPI-linked ephrin receptor activity | ||
| transmembrane-ephrin receptor activity | ||
| epidermal growth factor receptor activity | ||
| fibroblast growth factor receptor activity |
| DO ID | Disease Name | Source |
|---|---|---|
| DOID:0050331 | lacrimoauriculodentodigital syndrome 1 | |
| DOID:0050660 | Beare-Stevenson cutis gyrata syndrome | |
| DOID:0050861 | colorectal adenocarcinoma | |
| DOID:0060992 | bent bone dysplasia syndrome 1 | |
| DOID:0081289 | Antley-Bixler syndrome | |
| DOID:0081290 | Antley-Bixler syndrome without disordered steroidogenesis | |
| DOID:0111337 | Jackson-Weiss syndrome | |
| DOID:10534 | stomach cancer | |
| DOID:11054 | urinary bladder cancer | |
| DOID:12960 | acrocephalosyndactylia |
| Species | Gene ID | Alliance of Genome Resources | Orthologous MAtrix |
|---|---|---|---|
| 100393573 | CALJA06750 | ||
| 100562611 | ANOCA04427 | ||
| 100598157 | NOMLE27293 | ||
| 100664128 | LOXAF02138 | ||
| 100932215 | SARHA08630 | ||
| 100952813 | OTOGA14112 | ||
| 100981139 | PANPA05624 | ||
| 101002495 | PAPAN03573 | ||
| 101033845 | SAIBB04040 | ||
| 101073665 | TAKRU39460 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025